Zenas Biopharma (ZBIO) PT Lowered to $43 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts ZBIO Hot Sheet
Price: $28.46 --0%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Zenas Biopharma (NASDAQ: ZBIO) to $43.00 (from $46.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. Bank names two leaders to payments sales team
- Verizon raises caps, accepts $664M in notes tender offers
- AmeriLife partners with Palantir to deploy AI across insurance ops
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
